Abstract:Background: Macrophage accumulation in the vascular wall is a hallmark of atherosclerosis. Studies showed that shifting of oxidized lipids-induced inflammatory macrophages towards an anti-inflammatory phenotype by promoting oxidative metabolism attenuated atherosclerosis progression. Therefore, this study aimed to investigate whether metformin, which has ameliorated atherosclerosis in animal models and clinical trials, modulated oxidized low-density lipoprotein (Ox-LDL) induced inflammatory status in macrophages by regulating cellular oxidative metabolism. Methods: Murine raw264.7 macrophages were incubated with Ox-LDL (50 μg/mL) in the presence or absence of metformin (15 μmol/L) for 24 h. Real-time polymerase chain reaction was used to quantify the transcription of classically activated (M1) pro-inflammatory and alternatively activated (M2) anti-inflammatory markers and mitochondrial DNA copy numbers. Cellular reactive oxygen species (ROS) production and mitochondrial membrane potential were detected by immunofluorescence. Cellular adenosine triphosphate (ATP) synthesis, glucose uptake, and lactic acid production were measured by commercial kit and normalized to cellular lysates. Western blotting analysis was performed to detect the expression of mitochondrial fusion/fission related proteins, enzymes mediating lipid metabolism and signaling pathway of glucose transport. Differences between groups were analyzed using one-way analysis of variance. Results: Metformin improved Ox-LDL-impaired anti-inflammatory phenotype in raw264.7 macrophages as shown by up-regulated transcription of anti-inflammatory markers including interleukin 10 (0.76 ± 0.04 vs. 0.94 ± 0.01, P = 0.003) and Resistin-like molecule alpha (0.67 ± 0.08 vs. 1.78 ± 0.34, P = 0.030). Conversely, Ox-LDL-diminished phosphorylation of Akt was up-regulated by metformin treatment (0.47 ± 0.05 vs. 1.02 ± 0.08, P = 0.040), associated with an improvement of mitochondrial function, characterized by decreased ROS generation (2.50 ± 0.07 vs. 2.15 ± 0.04, P = 0.040), increased lipid oxidation, and elevated cellular ATP production (0.026 ± 0.001 vs. 0.035 ± 0.003, P = 0.020). Moreover, metformin-mediated Akt activation increased Akt substrate of 160 kDa (AS160) phosphorylation (0.51 ± 0.04 vs. 1.03 ± 0.03, P = 0.0041), promoted membrane translocation of glucose transporter 1, and increased glucose influx into the cells (4.78 ± 0.04 vs. 5.47 ± 0.01, P < 0.001). Conclusion: This study suggested that targeting macrophage metabolism with new or existing drugs had therapeutic potential for the prevention and treatment of diabetes-accelerated atherosclerosis.

Metformin affects the characteristics of HepG2 cells by regulating macrophage polarization in a microenvironment

Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling

Metformin's Antitumour and Anti‐angiogenic Activities Are Mediated by Skewing Macrophage Polarization

Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages.

Metformin impacts the differentiation of mouse bone marrow cells into macrophages affecting tumour immunity

Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer

Metformin Regulates Gut Microbiota Abundance to Suppress M2 Skewing of Macrophages and Colorectal Tumorigenesis in Mice

PlGF Signaling and Macrophage Repolarization Contribute to the Anti-Neoplastic Effect of Metformin

Metformin Triggers Apoptosis and Induction of the G0/G1 Switch 2 Gene in Macrophages

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Metformin decreases <i>Cyp26a1</i> to prevent hepatocarcinogenesis through down- regulating CD8<sup>+</sup> T cells

Metformin Inhibited GSDME to Suppress M2 Macrophage Pyroptosis and Maintain M2 Phenotype to Mitigate Cisplatin-Induced Intestinal Inflammation

Metabolic Switching in the Hypoglycemic and Antitumor Effects of Metformin on High Glucose Induced HepG2 Cells

Metformin Alleviates Colitis-Associated Colorectal Cancer Via Inhibition of the TLR4/MyD88/NFκB/MAPK Pathway and Macrophage M2 Polarization

Metformin Shows Anti‐inflammatory Effects in Murine Macrophages Through Dicer/microribonucleic Acid‐34a‐5p and Microribonucleic Acid‐125b‐5p

Metformin Decreases Il-22 Secretion To Suppress Tumor Growth In An Orthotopic Mouse Model Of Hepatocellular Carcinoma

Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells.

Metformin Alters the Expression Profiles of Micrornas in Human Pancreatic Cancer Cells

Metformin, Macrophage Dysfunction and Atherosclerosis

Metformin improved oxidized low-density lipoprotein-impaired mitochondrial function and increased glucose uptake involving Akt-AS160 pathway in raw264.7 macrophages